Director Marianne De Backer resigns from Arrowhead board effective April 2, 2023

ARROWHEAD PHARMACEUTICALS, INC.

Marianne De Backer notified Arrowhead of her resignation as director, effective April 2, 2023.
De Backer served as independent director, on Audit, Compensation, and as Chair of Nomination Committee.
Resignation due to her appointment as CEO and director of Vir Biotechnology; no disagreement with Arrowhead.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Marianne De Backer

director

ARWR · ARROWHEAD PHARMACEUTICALS, INC.

Effective: 2023-04-02
Filed: February 14, 2023, 6:59 PM ET

On February 11, 2023, Marianne De Backer , a director of Arrowhead Pharmaceuticals, Inc. (the “Company”), notified the Company of her decision to resign as a director, effective as of April 2, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Marianne De Backer resigned as director at ARROWHEAD PHARMACEUTICALS, INC..

Action: resigned
Role: director

Exact text from the filing

On February 11, 2023, Marianne De Backer , a director of Arrowhead Pharmaceuticals, Inc. (the “Company”), notified the Company of her decision to resign as a director, effective as of April 2, 2023.

View on SEC.gov

ARROWHEAD PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-003560

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.